Mitoxantrone
Novantrone (mitoxantrone) is a small molecule pharmaceutical. Mitoxantrone was first approved as Novantrone on 1987-12-23. It is used to treat breast neoplasms, lymphoma, multiple sclerosis, myeloid leukemia acute, and pain amongst others in the USA. It is known to target DNA topoisomerase 2-alpha and DNA topoisomerase 2-beta.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
nervous system diseases | D009422 |
urogenital diseases | D000091642 |
hemic and lymphatic diseases | D006425 |
skin and connective tissue diseases | D017437 |
immune system diseases | D007154 |
signs and symptoms pathological conditions | D013568 |
psychological phenomena | D011579 |
musculoskeletal and neural physiological phenomena | D055687 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mitoxantrone hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NOVANTRONE | EMD Serono | N-019297 DISCN | 1987-12-23 | 3 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
mitoxantrone | ANDA | 2012-05-31 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
J9293 | Injection, mitoxantrone hydrochloride, per 5 mg |
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypercholesterolemia | D006937 | HP_0003124 | — | 3 | 6 | — | — | 9 | |
Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | 3 | 2 | — | — | 5 |
Dyslipidemias | D050171 | HP_0003119 | — | 3 | 2 | — | — | 5 | |
Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | 3 | 2 | — | — | 5 |
Metabolic brain diseases | D001928 | G93.41 | — | 3 | 2 | — | — | 5 | |
Lipid metabolism disorders | D052439 | — | 3 | 2 | — | — | 5 | ||
Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | 2 | 2 | — | — | 4 |
Inborn genetic diseases | D030342 | EFO_0000508 | — | 2 | 2 | — | — | 4 | |
Newborn infant diseases | D007232 | — | 2 | 2 | — | — | 4 | ||
Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | 1 | 3 | — | — | 4 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 5 | — | — | — | — | 5 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | MITOXANTRONE |
INN | mitoxantrone |
Description | Mitoxantrone is a dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8. It has a role as an antineoplastic agent and an analgesic. |
Classification | Small molecule |
Drug class | antineoplastics, anthraquinone derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21 |
Target
Agency Approved
No data
Alternate
TOP2A
TOP2A
TOP2B
TOP2B
Organism
Homo sapiens
Gene name
TOP2A
Gene synonyms
TOP2
NCBI Gene ID
Protein name
DNA topoisomerase 2-alpha
Protein synonyms
DNA gyrase, DNA topoisomerase (ATP-hydrolyzing), DNA topoisomerase II, 170 kD, DNA topoisomerase II, alpha isozyme, topoisomerase (DNA) II alpha 170kDa
Uniprot ID
Mouse ortholog
Top2a (21973)
DNA topoisomerase 2-alpha (Q01320)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,151 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mitoxantrone
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
275 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more